Executives
-
Graham Jonathan PEVP & Gen. Counsel & Secy. -
Khosla RachnaSVP, Business Development
-
Busch Matthew C.VP, Finance & CAO
-
Grygiel Nancy A.SVP & CCO
-
Santos EstebanEVP, Operations
-
Reese David MEVP & Chief Technology Officer
-
Miller DerekSVP, Human Resources
-
Griffith Peter H.EVP & CFO
-
Gordon MurdoEVP, Global Commercial Ops
-
Bradner James E.EVP, R&D, & Chief Sci. Officer
?
Busch Matthew C.
VP, Finance & CAO
Amgen Inc.
US, Thousand Oaks [HQ]
CIK
1987926
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
4,932
Price per Share :
$272.11
Equivalence :
$1,342,046.52
Transaction History
-
A4,932 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/07/24
-
Footnotes
-
-
Footnotes:#1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.#2 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027; and 333 RSUs which will vest in installments of 109 on 5/7/2026, 110 on 5/7/2027, and 114 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#3 These shares include 112 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
A4,799 Shares After TransactionValue : $n/a$0.0Transaction Date : 03/06/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 115 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F4,770 Shares After TransactionValue : $1,511,660.70$59,895.99Transaction Date : 11/05/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Plan): 43 RSUs which will vest on 4/30/2025; 509 RSUs which will vest on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027; and 333 RSUs which will vest in installments of 109 on 5/7/2026, 110 on 5/7/2027, and 114 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 90 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F4,653 Shares After TransactionValue : $1,285,996.14$4,698.46Transaction Date : 04/30/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 125 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F4,626 Shares After TransactionValue : $1,283,113.62$7,488.99Transaction Date : 05/02/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 43 RSUs which will vest on 4/30/2025; 1,003 RSUs which will vest in installments of 494 on 11/5/2024 and 509 on 11/5/2025; 144 RSUs which will vest in installments of 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 121 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.